Contact Us
Drug Search Results
More Filters [+]

Zalcitabine

Alternative Names: zalcitabine, hivid
Latest Update: 2022-01-31
Latest Update Note: News Article

Product Description

Zalcitabine is an analogue of the nucleoside deoxycytidine which, when intracellularly converted to an active triphosphate metabolite, inhibits replication of human immunodeficiency virus (HIV). Zalcitabine is thought to act in the early phase of HIV replication by inhibiting reverse transcriptase and terminating the viral DNA chain. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1281077/)

Mechanisms of Action: DNA Polymerase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | Germany | India | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Slovenia | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zalcitabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

01/31/2022

News Article

 Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

04/15/2019

News Article

 Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions